Expert Profile

Share QR code Edit Profile

Claes Wahlestedt

Pending Rank At Professor; Assoc. Dean

PSYCHIATRY & BEHAVIORAL SCIENCES | SCHOOL OF MEDICINE

View:

Select
All (all in one) Research Terms and Keywords Background Publications Co-Investigator Network Websites Contact

All
Research
Background
Publications
Network
Websites
Contact

Research Terms & Keywords

Research Terms

Life Sciences Medical Sciences Science

Industries

Health Care

Research Projects

Ends

Title

05-2027

Epigenetics of alcohol compulsion - Resubmission - 1 Epigenetics of alcohol compulsion - Resubmission - 1

05-2026

Menopause, DNA Damage & Epigenetics in AD Menopause, DNA Damage & Epigenetics in AD

04-2026

LLBELLA: IDE DSTP for Pediatric Sarcoma LLBELLA: IDE DSTP for Pediatric Sarcoma

04-2026

LLBELLA: IDE DSTP for Pediatric Sarcoma LLBELLA: IDE DSTP for Pediatric Sarcoma

02-2026

WAHLESTEDT: ED & ETHEL MOORE WAHLESTEDT: ED & ETHEL MOORE

03-2024

The beneficial role of exercise-induced The beneficial role of exercise-induced

05-2023

Contributions of Histone Deacetylase 8 (HDAC8) to Alzheimer’s Disease Pathogenesis.. Contributions of Histone Deacetylase 8 (HDAC8) to Alzheimer’s Disease Pathogenesis..

05-2023

Contributions of Histone Deacetylase 8 (HDAC8) to Alzheimer’s Disease Pathogenesis.. Contributions of Histone Deacetylase 8 (HDAC8) to Alzheimer’s Disease Pathogenesis..

02-2023

Menopause and AD Menopause and AD

02-2023

Menopause and AD Menopause and AD

09-2022

BRD4 Inhibitor BRD4 Inhibitor

09-2022

BRD4 Inhibitor BRD4 Inhibitor

08-2021

EPIGENETIC SIGNALING PATHWAYS CONTRIBUTING TO ALCOHOL DEPEND EPIGENETIC SIGNALING PATHWAYS CONTRIBUTING TO ALCOHOL DEPEND

08-2021

EPIGENETIC SIGNALING PATHWAYS CONTRIBUTING TO ALCOHOL DEPEND EPIGENETIC SIGNALING PATHWAYS CONTRIBUTING TO ALCOHOL DEPEND

05-2021

Leveraging the Human Non-Coding Transcriptome to Identify Therapeutics for Healthy Aging and Alzheimers Disease Leveraging the Human Non-Coding Transcriptome to Identify Therapeutics for Healthy Aging and Alzheimers Disease

05-2021

03-2021

PRECLINICAL INVESTIGATION OF AN OPTIMIZED FORMULATION OF RES PRECLINICAL INVESTIGATION OF AN OPTIMIZED FORMULATION OF RES

03-2021

PRECLINICAL INVESTIGATION OF AN OPTIMIZED FORMULATION OF RES PRECLINICAL INVESTIGATION OF AN OPTIMIZED FORMULATION OF RES

04-2018

SMALL MOLECULE INDETIFICATION FOR THE NOCICEPTIN RECEPTOR TO SMALL MOLECULE INDETIFICATION FOR THE NOCICEPTIN RECEPTOR TO

04-2018

SMALL MOLECULE INDETIFICATION FOR THE NOCICEPTIN RECEPTOR TO SMALL MOLECULE INDETIFICATION FOR THE NOCICEPTIN RECEPTOR TO

01-2018

EPIGENETIC MODULATION OF ALZHEIMER'S DISEASE HALLMARKS EPIGENETIC MODULATION OF ALZHEIMER'S DISEASE HALLMARKS

01-2018

EPIGENETIC MODULATION OF ALZHEIMER'S DISEASE HALLMARKS EPIGENETIC MODULATION OF ALZHEIMER'S DISEASE HALLMARKS

12-2017

ANTISENSE RNA MEDIATED EPIGENETIC REGULATION OF BRAIN DERIVE ANTISENSE RNA MEDIATED EPIGENETIC REGULATION OF BRAIN DERIVE

12-2017

ANTISENSE RNA MEDIATED EPIGENETIC REGULATION OF BRAIN DERIVE ANTISENSE RNA MEDIATED EPIGENETIC REGULATION OF BRAIN DERIVE

03-2017

LONG NONCODING RNAS AND CHROMATIN REGULATION IN COCAINE ADDI LONG NONCODING RNAS AND CHROMATIN REGULATION IN COCAINE ADDI

03-2017

LONG NONCODING RNAS AND CHROMATIN REGULATION IN COCAINE ADDI LONG NONCODING RNAS AND CHROMATIN REGULATION IN COCAINE ADDI

06-2015

Epigenetic approach for the treatment of alzheimer's disease Epigenetic approach for the treatment of alzheimer's disease

06-2014

REGULATION OF ALZHEIMER'S DISEASE RELATED GENES BY NATURAL ANTISENSE TRANSCRIPTS. REGULATION OF ALZHEIMER'S DISEASE RELATED GENES BY NATURAL ANTISENSE TRANSCRIPTS.

01-2014

REGULATORY RNAs AS MEDIATORS AND MEDIATORS AND BIOMARKERS IN ALZHEIMER'S DISEASE REGULATORY RNAs AS MEDIATORS AND MEDIATORS AND BIOMARKERS IN ALZHEIMER'S DISEASE

03-2013

DISCOVERY OF POTENT AND SELECTIVE NEUROPEPTIDE Y Y2 RECEPTOR ANTAGONIST PROBES DISCOVERY OF POTENT AND SELECTIVE NEUROPEPTIDE Y Y2 RECEPTOR ANTAGONIST PROBES

02-2013

ROLE OF NONCODING RNAs SCHIZOPHRENIA ROLE OF NONCODING RNAs SCHIZOPHRENIA

12-2012

Development of Optimized Stategies for Reducing Beta-Secretase Activity in Vivo Development of Optimized Stategies for Reducing Beta-Secretase Activity in Vivo

Degrees

Ph.D., Pharmacology

Univ. Lund, Sweden ▪ 1987
M.D., Medicine

Univ Lund, Sweden ▪ 1986

Publications

Search Google Scholar for Claes Wahlestedt

More Publications

>200 peer reviewed scientific publications plus reviews and patents

Co-Investigator Network

Inactive Expert

Mohammad Faghihi

Asst. Professor

University of Miami

Psychiatry & Behavioral Sciences, University Of Miami Leonard M. Miller School Of Medicine

mfaghihi@med.miami.edu

Inactive Expert

Mohammad Faghihi

University of Miami

MSOM Center For Therapeutic Innovation, Medical

mfaghihi@miami.edu

Websites

Search Google Scholar for Claes Wahlestedt

Contact Information

cwahlestedt@med.miami.edu

3052437694

1501 NW 10 Avenue
BRB-407
Miami, FL 33136-1000

Profile QR code

What is this?

Claes Wahlestedt

Pending Rank At Professor; Assoc. Dean

PSYCHIATRY & BEHAVIORAL SCIENCES | SCHOOL OF MEDICINE

Research Terms & Keywords

Research Projects

Degrees

Publications

More Publications

Co-Investigator Network

Websites

Contact Information

About

Discover

Connect

Keyword Search

Browse by STEM